Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristin Elliott

Nurse Practitioner Port Huron, MI Nurse Practitioner

NPI 1801029418 CMS profile 10935769

2615 Electric Avenue, Port Huron, MI 48060

Open in the dashboard

General payments

$6,633

315 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristin Elliott of Port Huron, MI is reported in the CMS Open Payments database as having received $6,633 across 315 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,041 25
2024 General $809 37
2023 General $1,194 53
2022 General $1,897 107
2021 General $1,691 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristin Elliott
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kristin Elliott were reported at $1,041. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kristin Elliott Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,691 $135 $40–$426 $132
2022 $1,897 $152 $48–$470 $149
2023 $1,194 $166 $54–$529 $160
2024 $809 $173 $55–$556 $164
2025 $1,041 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,126 36 payments
  2. Amgen Inc. $973 28 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $568 26 payments
  4. Philips Electronics North America Corporation $350 20 payments
  5. AbbVie, Inc. $332 21 payments
  6. Lilly USA, LLC $291 20 payments
  7. Grifols USA, LLC $288 14 payments
  8. Abbott Laboratories $257 21 payments
  9. Corcept Therapeutics $227 14 payments
  10. Merck Sharp & Dohme Corporation $194 10 payments
  11. Other $2,027 105 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,633 315 payments
Products named General payments · program years 2021–2025
  1. TEZSPIRE Inflammation $775 16 payments
  2. GLASSIA $510 24 payments
  3. FASENRA $346 13 payments
  4. TEZSPIRE Respiratory $336 9 payments
  5. Prolastin-C Liquid $288 14 payments
  6. (7999) SRC Und $267 13 payments
  7. Korlym $227 14 payments
  8. DIFICID $161 8 payments
  9. SYNTHROID $160 11 payments
  10. JARDIANCE $149 8 payments
  11. Other $3,882 223 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

111

Median for Nurse Practitioner: 389

Drug cost

$3,329

Median for Nurse Practitioner: $21,885

Branded share of claims

37.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Novolog Insulin Aspart Brand 14 $980
Lantus Insulin Glargine,hum.Rec.Anlog Brand 15 $933
Insulin Syringe Syringe-Needle,insulin,0.5 Ml Brand 13 $620
Montelukast Sodium Generic 20 $398
Levothyroxine Sodium Generic 12 $141
Alprazolam Generic 11 $110
Prednisone Generic 13 $77
Lisinopril Generic 13 $70

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $128
$128 — —
Prolastin-C Liquid
  • Grifols USA, LLC $89
$89 — —
Xolair
  • Genentech USA, Inc. $65
$65 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $62
$62 — —
Zemaira
  • Relypsa, Inc. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

315 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record